HU: Tobacco plant can produce anti-malaria drug

Researchers used plant to produce effective anti-malaria drug; combating malaria is 1 of the 8 Millennium Development Goals.

December 19, 2011 05:51
2 minute read.
Tobacco plants

Tobacco plants 311. (photo credit: Thinkstock/Imagebank)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Although tobacco in the form of cigarettes is generally recognized as being a killer of millions, the plant has been used by Hebrew University researchers to produce an effective anti-malaria drug.

A genetically engineered form of artemisinin, a natural compound that produces large quantities of the anti-malaria drug - was announced Sunday by the Yissum Research Development Company – the Hebrew University of Jerusalem’s technology transfer company. The biosynthesis method - a novel way of producing Artemisia annua, which is naturally produced by sweet wormwood plants - was developed by Prof. Alexander Vainstein and the research was published as a letter in the latest issue of the journal Nature Biotechnology.

Be the first to know - Join our Facebook page.

Combating malaria is one of the eight Millennium Development Goals described in the UN Millennium Declaration signed by all UN members 11 years ago. An important way to control the deadly parasitic disease that affects mostly the Third World is prompt and effective treatment with artemisinin-based combination therapies.

But low-cost artemisininbased drugs are in short supply because of the high cost of obtaining the natural or chemically synthesized drug. Despite extensive efforts made in the last decade in metabolic engineering of the drug in both microbial and heterologous plant systems, no one has been able to produce artemisinin itself.

Malaria, caused by the Plasmodium parasite, is transmitted via mosquitoes. Symptoms include fever, headache and vomiting, and they usually appear between 10 and 15 days after the mosquito bite. If left untreated, malaria can quickly become life threatening by disrupting the blood supply to vital organs. Over three billion people are at risk of malaria, and about 250 million new malaria cases occur each year, causing nearly a million deaths, mostly of people living in poor countries.

Vainstein and graduate student Moran Farhi developed genetically engineered tobacco plants carrying genes encoding the entire biochemical pathway needed for producing artemisinin. In light of tobacco’s high biomass and rapid growth, this invention will enable a cheap production of large quantities of the drug, paving the way for the development of a sustainable plant-based platform for the commercial production of an antimalarial drug, said Yissum, which patented it and is now seeking a partner for its further development.

Yissum CEO Yaacov Michlin said Vainstein’s technology provides for the first time, the opportunity for manufacturing affordable artemisinin by using tobacco plants.


“We hope this invention will eventually help control this prevalent disease, for the benefit of many millions of people around the globe and in particular in the developing world.”

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

August 31, 2014
Weizmann scientists bring nature back to artificially selected lab mice